The major highlight of the study by Bürli’s group3 is the actualization of such a potential strategyfor the treatment of PD symptoms by engaging in the development ofan α6*-nAChR-selective antagonist, which should be a more accessibleachievement than development of a selective agonist. The gene discussed is TWF1; the disease is Parkinson disease.